You are not alone. Here is where to start: learn the basics, find a specialist or center that sees EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition, look for clinical trials, and connect with others living with it — all in one place.
Open the full EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition hub →EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition is a rare condition. Tomeko brings together the specialists, research, clinical trials, treatments and community for EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition so you can go from overwhelmed to oriented. For authoritative medical detail, see the reference sources below.
Identifiers: GARD 0028183
Start by learning the basics from an authoritative source, find a specialist or center that sees EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition, and connect with a patient organization. Tomeko brings these together on one hub.
Use Tomeko's specialist and Centers-of-Excellence directories to find clinicians who treat EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition, filtered to your area.
Tomeko shows live, recruiting studies for EGLN1-related erythrocytosis and pheochromocytoma/paraganglioma predisposition from ClinicalTrials.gov on the hub.